The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.

TitleSubretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.
Publication TypeJournal Article
Year of Publication2014
AuthorsSymeonidis, C., Dastiridou A., Konidaris V., Brazitikos P., & Androudi S.
JournalOcul Immunol Inflamm
Volume22
Issue6
Pagination497-500
Date Published2014 Dec
ISSN1744-5078
KeywordsAntibodies, Monoclonal, Humanized, Dose-Response Relationship, Drug, Fluorescein Angiography, Fundus Oculi, Humans, Male, Middle Aged, Off-Label Use, Ranibizumab, Retina, Tomography, Optical Coherence, Uveitis, Posterior, Visual Acuity
Abstract

PURPOSE: The subretinal fibrosis and uveitis (SFU) syndrome is a rare multifocal posterior uveitis characterized by progressive subretinal fibrosis and significant visual loss.METHODS: Slit-lamp examination, dilated fundoscopy, fluorescein angiography, Spectral Domain-Optical Coherence Tomography (SD-OCT) and laboratory testing were employed.RESULTS: A 52-year-old male presented with bilateral (best-corrected visual acuity: 2/10) visual loss. Clinical examination revealed bilateral anterior uveitis with posterior synechiae and posterior uveitis. Medical workup revealed no pathologic findings. Treatment included 1 gr intravenous prednisone followed by oral prednisone, immunosuppresive therapy and three ranibizumab injections in the right eye with no improvement. One year later, there was significant subretinal fibrosis. In the second year follow-up, the picture was slightly worse, with persisting bilateral macular edema and fibrosis.CONCLUSIONS: This is the first SFU syndrome report monitored with SD-OCT. This novel imaging modality can localize the lesion level, guide the therapeutic approach and may prove helpful in assessing disease prognosis.

DOI10.3109/09273948.2013.841959
Alternate JournalOcul. Immunol. Inflamm.
PubMed ID24131103

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.